doi:10.2337/dc23-S011 Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jdar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbll T
The protective effects of GLP-1s on the kidneys are thought to be mediated through both direct and indirect mechanisms
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) reviewed the evidence in 2024 and concluded there is no causal link between GLP-1 receptor agonists and increased suicide risk, though continued monitoring is advised
Final Thoughts Doctors and researchers do not know that GLP-1 medications like Ozempic and Wegovy can cause blood in stool
it represents the removal of the entire safety framework that legitimate programs provide
New approaches for its evaluation and management